Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of “Buy” by Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned a consensus rating of “Buy” from the eight research firms that are covering the stock, MarketBeat reports. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $43.17.

A number of brokerages recently issued reports on ORKA. Leerink Partnrs upgraded shares of Oruka Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 17th. HC Wainwright reiterated a “buy” rating and issued a $45.00 price objective on shares of Oruka Therapeutics in a report on Thursday, October 31st. Wedbush assumed coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 target price on the stock. Lifesci Capital assumed coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set an “outperform” rating and a $41.00 price target for the company. Finally, Stifel Nicolaus initiated coverage on Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 price target on the stock.

Oruka Therapeutics Stock Performance

NASDAQ:ORKA opened at $25.65 on Thursday. The company has a market capitalization of $31.04 million, a PE ratio of -4.26 and a beta of 0.87. Oruka Therapeutics has a 1 year low of $18.72 and a 1 year high of $53.88. The stock has a fifty day simple moving average of $26.83.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Great Point Partners LLC acquired a new stake in shares of Oruka Therapeutics during the third quarter worth $12,614,000. FMR LLC acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at $114,763,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Oruka Therapeutics in the 3rd quarter worth about $1,037,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.